Establishment Labs Holdings Inc. (NASDAQ:ESTA) Principal shareholder acquires $2,450,350.00 in stock
Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) principal shareholder Jw Asset Management, Llc purchased 35,000 shares in a trade on Wednesday, April 13. The shares were purchased at an average price of $70.01 per share, for a total transaction of $2,450,350.00. Following the purchase, the insider now directly owns 3,177,485 shares of the company, valued at approximately $222,455,724.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Large shareholders who own more than 10% of a company’s stock are required to disclose their sales and purchases to the SEC.
Jw Asset Management, Llc also recently completed the following transactions:
- On Monday, March 14, Jw Asset Management, Llc purchased 10,000 shares of Establishment Labs. The shares were purchased at an average cost of $52.63 per share, with a total value of $526,300.00.
- On Wednesday, March 2, Jw Asset Management, Llc acquired 5,000 shares of Establishment Labs. The shares were purchased at an average cost of $59.45 per share, with a total value of $297,250.00.
- On Monday, February 28, Jw Asset Management, Llc acquired 10,000 shares of Establishment Labs. The shares were purchased at an average cost of $59.42 per share, with a total value of $594,200.00.
ESTA shares opened at $71.87 on Friday. Establishment Labs Holdings Inc. has a fifty-two week low of $46.93 and a fifty-two week high of $88.66. The company has a debt ratio of 1.02, a quick ratio of 2.66 and a current ratio of 3.55. The stock’s 50-day simple moving average is $60.50 and its 200-day simple moving average is $63.95.
Establishment Labs (NASDAQ:ESTA – Get Rating) last released its quarterly results on Tuesday, March 1. The company reported ($0.60) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.33) by ($0.27). Establishment Labs had a negative return on equity of 64.87% and a negative net margin of 32.47%. During the same period of the previous year, the company posted an EPS of ($0.23). Stock analysts expect Establishment Labs Holdings Inc. to post -1.27 earnings per share for the current fiscal year.
Major investors have recently changed their positions in the company. Macquarie Group Ltd. acquired a new position in Establishment Labs in the third quarter worth approximately $38,000. Deutsche Bank AG increased its position in shares of Establishment Labs by 120.5% during the third quarter. Deutsche Bank AG now owns 679 shares of the company worth $49,000 after buying 371 more shares last quarter. Advisor Group Holdings Inc. increased its position in shares of Establishment Labs by 502.7% during the third quarter. Advisor Group Holdings Inc. now owns 904 shares of the company worth $65,000 after purchasing an additional 754 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Establishment Labs during the second quarter for a value of approximately $180,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of Establishment Labs during the second quarter for a value of approximately $206,000. 68.57% of the shares are held by institutional investors.
ESTA has been the subject of several analyst reports. Goldman Sachs Group lowered its price target on Establishment Labs from $78.00 to $67.00 and set a “neutral” rating for the company in a Monday, March 21 research report. Zacks Investment Research downgraded Establishment Labs from a “hold” rating to a “sell” rating in a Friday, March 4 research note. One research analyst has rated the security with a sell rating, one has issued a hold rating and three have issued a buy rating for the security. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $84.40.
Establishment Labs Company Profile (Get a rating)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 soft silicone gel filled round breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, and also distributes the Puregraft line of products for the harvesting and redistribution of autologous adipose tissue.
Receive daily news and reviews for facility labs – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Establishment Labs and related companies with MarketBeat.com’s FREE daily newsletter.